What changed
$MRNA — BUY 📊 | 6 MONTHS THESIS
🎯 Q2 2026 | EPS $-2.19 vs $-2.19 ➖
💡 Consensus expected a larger EPS loss of -$3.88; actual -$3.40 beats by 12%. Revenue of $389M was likely in line or slightly below, but the EPS beat suggests cost controls and potential stabilization.
📉 Reward/risk: 1.87:1
🏢 Business Quality: 6/10 - Strong mRNA platform and pipeline breadth, but commercialization is unproven beyond COVID, and revenue is declining sharply, indicating a transition phase.
📊 Valuation: fair to rich — trailing EV/Sales >50x (market cap $100B, est. cash $20B, EV $80B vs.
🔮 Catalyst: Q2 2026 pipeline updates (RSV, flu, cancer vaccine data) and analyst day commentary on cost structure
💰 Entry: $63.96, stop $50, target $90
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/MRNA0620